Potential biochemical markers of chronic bronchitis and bronchial asthma. Current state of the problem

The literature review, according to recent publications, systematizes modern ideas about new biochemical markers of bronchopulmonary pathology, namely chronic obstructive pulmonary disease, chronic bronchitis and bronchial asthma. Information on potential biochemical markers associated with pathology of the bronchopulmonary system is presented: pulmonary activation regulated chemokine (chemokine ligand CCL20), surfactant proteins A and D, pentraxin-3, defensins, alpha-1 antitrypsin, Clara cell protein, interleukin-19, resistin-like molecules. For each biomolecule, its characteristic, biological properties and effects are described, as well as the results of experimental and clinical studies of its effects in bronchopulmonary pathology, the association of elevated blood levels of a biomolecule with clinical manifestations of diseases. It is concluded that today there are a considerable number of new potential biomarkers of the respiratory system diseases for early and effective diagnosis, prevention and treatment of diseases, however, the effects of some of them are either insufficiently studied or contradictory and require further research, which is actively ongoing in the whole world and in Russia.

1. Borkina A.N. The role of Clara cells in the histo-physiology of bronchial epithelium and their importance in the development of pulmonary pathology. Pulmonologiya = Pulmonology. 2007; (5). 94-99. [In Russian].

2. Alpha-1 antitrypsin deficiency in adults. Recommendations of Russian Respiratory Society. Ministry of Health of the Russian Federation, 2017. [In Russian].

3. Didkovsky N.A., Zharova M.A. The value of hereditary factors in the development of emphysema. Ter-apevticheskiy arkhiv = Therapeutic archive. 2006; (3): 70-74. [In Russian].

4. Zhigaltsova-Kuchinskaya O.A., Sivitskaya L.N., Danilenko N.G., Zhigaltsov A.M., Nagornov I.V., Me-telsky S.M. Alpha-1-antitrypsin deficiency: genetic fundamentals, epidemiology, role in the development of bronchopulmonary pathology. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta = Vestnik of Vitebsk State Medical University. 2015; 14 (6): 39-52. [In Russian].

5. Kovalkova N.A., Ragino Yu.I., Logvinenko N.I., Merekina E.V., Voevoda M.I. The value of surfactant proteins in the diagnosis of therapeutic diseases. Tera-pevticheskiy arkhiv = Therapeutic archive. 2015; 87 (1): 115-119. doi: 10.17116/terarkh2015871115-119 [In Russian].

6. Lyamina S.V., Vedenikin T.Yu., Malyshev I.Yu. A modern approach to the analysis of the immune response in lung diseases: surfactant protein D and its role. Sovremennye problemy nauki i obrazovaniya = Modern problems of Science and Education. 2011; (4): 1-2. [In Russian].

7. Mikerov A.N. The role of surfactant protein A in the immune defense of the lungs. Fundamental’nye issledovaniya = Fundamental Research. 2012; (2): 204-207. [In Russian].

8. Nazarov P.G. Pentraxins in reactions of innate and acquired immunity, organization of the matrix, fertility. Meditsinskiy akademicheskiy zhurnal = Medical Academic Journal. 2010; (4): 107-124. [In Russian].

9. Solovyova O.G. Deficiency A1 antitrypsin in the practice of a pulmonologist. Pulmonologiya = Pulmonology. 2015; 25 (4): 505-508. doi: 10.18093/086901892015254505508 [In Russian].

10. Azzurri A., Sow O.Y., Amedei A., Bah B., Di-allo S., Peri G., Benagiano M., D’Elios M.M., Man-tovani A., Del Prete G. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005; 7 (1): 1-8. doi: 10.1016/j.micinf.2004.09.004

11. Bellinghausen I., Reuter S., Martin H., Maxein-er J., Luxemburger U., Tureci O., Grabbe S., Taube C., Saloga J. Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity. J. Allergy Clin. Immunol. 2012; 130 (6): 1384-1393. doi: 10.1016/jjaci.2012.08.039

12. Bozza S., Bistoni F., Gaziano R., Pitzurra L., Zelante T., Bonifazi P., Perruccio K., Bellocchio S., Neri M., Iorio A.M., Salvatori G., de Santis R., Calvit-ti M., Doni A., Garlanda C., Mantovani A., Romani L. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood. 2006; 108 (10): 3387-3396. doi: 10.1182/blood-2006-03-009266

13. Braido F., Riccio A.M., Guerra L., Gamalero C., Zolezzi A., Tarantini F., de Giovanni B., Folli C., Des-calzi D., Canonica G.W. Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respir. Med. 2007; 101 (10): 2119-2124. doi: 10.1016/j.rmed.2007.05.023

14. Breviario F., d’Aniello E.M., Golay J., Peri G., Bottazzi B., Bairoch A., Saccone S., Marzella R., Pre-dazzi V, Rocchi M. et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J. Biol. Chem. 1992; 267 (31): 22190-22197.

15. Brinker K.G., Gamer H., Wright J.R. Surfactant protein A modulates the differentiation of murine bone marrow-derived dendritic cells. J. Physiol. Lung Cell Mol. Physiol. 2003; 284: L232-L241.

16. Broeckaert F., Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin. Exp. Allergy. 2000; 30 (4): 469-475. doi: 10.1046/j.1365-2222.2000.00760.x

17. Caramori G., Adcock I.M., di Stefano A., Chung K.F. Cytokine inhibition in the treatment of COPD. Int. J. Chron. Obstruct. Pulmon Dis. 2014; 9: 397-412. doi: 10.2147/COPD.S42544

18. Chen H., Wang Y, Bai C., Wang X. Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. J. Proteomics. 2012; 75: 2835-2843. doi: 10.1016/jjprot.2012.01.027

19. Chenivesse C., Chang Y., Azzaoui I., Ait Yahia S., Morales O., Ple C., Foussat A., Tonnel A.B., Delhem N., Yssel H., Vorng H., Wallaert B., Tsico-poulos A. Pulmonary CCL18 recruits human regulatory T cells. J Immunol. 2012; 189 (1): 128-137. doi: 10.4049/jimmunol.1003616

20. De Nadai' P., Charbonnier A.S., Chenivesse C., Senechal S., Fournier C., Gilet J., Vorng H., Chang Y., Gosset P., Wallaert B., Tonnel A.B., Lassalle P., Tsico-poulos A. Involvement of CCL18 in allergic asthma. J. Immunol. 2006; 176 (10): 6286-6293. doi: 10.4049/jimmunol.176.10.6286

21. Dilek F., Emin O., Gtiltepe B., Yazici M., Ca-kir E., Gedik A.H. Evaluation of nasal fluid P-defensin 2 levels in children with allergic rhinitis. Turk. Pediatri. Ars. 2017; 52 (2): 79-84. doi: 10.5152/TurkPediatri-Ars.2017.4497

22. Eden E., Strange C., Holladay B., Xie L. Asthma and allergy in alpha-1 antitrypsin deficiency. Respir. Med. 2006; 100 (8): 1384-1391. doi: 10.1016/j.rmed.2005.11.017

23. Emmanouil P., Loukides S., Kostikas K., Pa-patheodorou G., Papaporfyriou A., Hillas G., Vamva-karis I., Triggidou R., Katafigiotis P., Kokkini A., Pa-piris S., Koulouris N., Bakakos P. Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma. Allergy. 2015; 70 (6): 711-714. doi: 10.1111/all.12603

24. Ermers M.J., Janssen R., Onland-Moret N.C., Hodemaekers H.M., Rovers M.M., Houben M.L., Kimpen J.L., Bont L.J. IL10 family member genes IL19 and IL20 are associated with recurrent wheeze after respiratory syncytial virus bronchiolitis. Pediatr. Res. 2011; 70 (5): 518-523. doi: 10.1203/PDR.0b013e31822f5863

25. Faiz A., Weckmann M., Tasena H., Vermeu-len C.J., van den Berge M., Ten Hacken N.H.T., Ha-layko A.J., Ward J.P.T., Lee T.H., Tjin G., Black J.L., Haghi M., Xu C.J., King G.G., Farah C.S., Oliver B.G., Heijink I.H., Burgess J.K. Profiling of healthy and asthmatic airway smooth muscle cells following interleu-kin-1beta treatment: a novel role for CCL20 in chronic mucus hypersecretion. Eur. Respir. J. 2018; 52 (2). doi: 10.1183/13993003.00310-2018

26. Fan C., Meuchel L.W., Su Q., Angelini D.J., Zhang A., Cheadle C., Kolosova I., Makarevich O.D., Yamaji-Kegan K., Rothenberg M.E., Johns R.A. Resis-tin-like molecule a in allergen-induced pulmonary vascular remodeling. Am. J. Respir. Cell Mol. Biol. 2015; 53 (3): 303-313. doi: 10.1165/rcmb.2014-0322OC

27. Fang C.L., Yin L.J., Sharma S., Kierstein S., Wu H.F., Eid G., Haczku A., Corrigan C.J. Resistinlike molecule-P (RELM-P) targets airways fibroblasts to effect remodelling in asthma: from mouse to man. Clin. Exp. Allergy. 2015; 45 (5): 940-952. doi 10.1111/cea.12481

28. Francis J.N., Sabroe I., Lloyd C.M., Durham S.R., Till S.J. Elevated CCR6+ CD4+ T lymphocytes in tissue compared with blood and induction of CCL20 during the asthmatic late response. Clin. Exp. Immunol. 2008; 152 (3): 440-447 doi: 10.1111/j.1365-2249.2008.03657.x

29. Guerra S., Halonen M., Vasquez M.M., Span-genberg A., Stern D.A., Morgan W.J., Wright A.L., Lavi I., Tares L., Carsin A.E., Dobano C., Barreiro E., Zock J.P., Martinez-Moratalla J., Urrutia I., Sunyer J., Keidel D., Imboden M., Probst-Hensch N., Hallberg J., Melen E., Wickman M., Bousquet J., Belgrave D.C., Simpson A., Custovic A., Anto J.M., Martinez F.D. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir. Med. 2015; 3 (8): 613-620. doi: 10.1016/S2213-2600(15)00196-4

30. Guerra S., Vasquez M.M., Spangenberg A., Halonen M., Martin R.J. Club cell secretory protein in serum and bronchoalveolar lavage of patients with asthma. J. Allergy Clin. Immunol. 2016; 138 (3): 932-934. doi: 10.1016/jjaci.2016.03.047

31. Haitham S., Ashry A., Strange C. COPD in individuals with the PiMZ alpha-1 antitrypsin genotype. Eur. Respir. Rev. 2017; 26 (146). pii 170068. doi: 10.1183/16000617.0068-2017

32. Hamai K., Iwamoto H., Ishikawa N., Hori-masu Y., Masuda T., Miyamoto S., Nakashima T., Ohshimo S., Fujitaka K., Hamada H., Hattori N., Kohno N. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and Sp-D as disease markers of idiopathic pulmonary fibrosis. Dis. Markers. 2016; 2016: 4759040. doi: 10.1155/2016/4759040

33. He X., Han B., Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am. J. Physiol. 2007; 292 (5): 1039-1049. doi: 10.1152/aj-plung.00490.2006

34. Kishore U., Greenhough T.J., Waters P., Shrive A.K., Mohammed R., Kamran M.F., Bernal A.L., Reid K.B., Madan T., Chakraborty T. Surfactant proteins SP-A and SP-D: structure, function and receptors.Mol. Immunol. 2006; 43 (9): 1293-1315. doi: 10.1016/j.molimm.2005.08.004

35. LeMessurier K.S., Palipane M., Tiwary M., Gavin B., Samarasinghe A.E. Chronic features of allergic asthma are enhanced in the absence of resistinlike molecule-beta. Sci. Rep. 2018; 8 (1): 7061. doi: 10.1038/s41598-018-25321-y

36. Liao S.C., Cheng Y.C., Wang Y.C., Wang C.W., Yang S.M., Yu C.K., Shieh C.C., Cheng K.C., Lee M.F., Chiang S.R., Shieh J.M., Chang M.S. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J. Immunol. 2004; 173 (11): 6712-6718. doi: 10.4049/jimmunol.173.11.6712

37. Mackay R.M., Grainge C.L., Lau L.C., Barber C., Clark H.W., Howarth P.H. Airway surfactant protein D deficiency in adults with severe asthma. Chest. 2016; 149 (5): 1165-1172. doi: 10.1016/j.chest.2015.11.012

38. Madan T., Kishore U., Singh M., Strong P., Clark H., Hussain E.M., Reid K.B.M., Sarma P.U. Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J. Clin. Invest. 2001; 107 (4): 467-475. doi: 10.1172/JCI10124

39. Mantovani A., Garlanda C., Doni A., Bottaz-zi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J. Clin. Immunol. 2008; 28 (1): 1-13. doi: 10.1007/s10875-007-9126-77

40. Mattar E.H., Almehdar H.A., Yacoub H.A., Uversky V.N., Redwan E.M. Antimicrobial potentials and structural disorder of human and animal defensins. Cytokine Growth Factor Rev. 2016; 28: 95-111. doi: 10.1016/j.cytogfr.2015.11.002

41. Munitz A., Cole E., Karo-Atar D., Finkel-man F.D., Rothenberg M.E. Resistin-like molecule-alpha regulates IL-13-induced chemokine production but not allergen-induced airway responses. Am. J. Respir. Cell Mol. Biol. 2012; 46 (5): 703-713. doi: 10.1165/rcmb.2011-0391OC

42. Obeidat M., Li X., Burgess S., Zhou G., Fish-bane N., Hansel N.N., Bosse Y., Joubert P., Hao K., Nickle D.C., van den Berge M., Timens W., Cho M.H., Hobbs B.D., de Jong K., Boezen M., Hung R.J., Rafaels N., Mathias R., Ruczinski I., Beaty T.H., Barnes K.C., Pare P.D., Sin D.D. Surfactant protein D is a causal risk factor for COPD: results of Mende-lian randomisation. Eur. Respir. J. 2017; 50 (5). doi: 10.1183/13993003.00657-2017

43. Oral H.B., Kotenko S.V., Yilmaz M., Mani O., Zumkehr J., Blaser K., Akdis C.A., Akdis M. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur. J. Immunol. 2006; 36: 380-388. doi: 10.1016/s0165-2478(03)00087-7

44. Reibman J., Hsu Y., Chen L.C., Bleck B., Gordon T. Airway epithelial cells release MIP-3a/CCL20 in response to cytokines and ambient particulate matter. Am. J. Respir. Cell Mol. Biol. 2003; 28 (6): 648-654. doi: 10.1165/rcmb.2002-00950C

45. Proud D. The role of defensins in virus-induced asthma. Curr. Allergy Asthma Rep. 2006; 6 (1): 81-85. doi: 10.1007/s11882-006-0015-6

46. Pini L., Tiberio L., Venkatesan N., Bezzi M., Corda L., Luisetti M., Ferrarotti I., Malerba M., Lomas D.A., Janciauskiene S., Vizzardi E., Modina D., Schiaffonati L., Tantucci C. The role of bronchial epithelial cells in the pathogenesis of COPD in Z alpha 1 antitrypsin deficiency. Respir. Res. 2014; 15 (1): 112. doi: 10.1186/s12931-014-0112-3

47. Sanmiguel C.J., Olaru F., Li J., Mohr E., Jensen E. Interleukin-1 regulates keratinocyte expression of T cell targeting chemokines through interleukin-1 receptor associated kinase-1 (IRAK1) dependent and independent pathways. Cell Signal. 2009; 21 (5): 685694. doi: 10.1016/j.cellsig.2009.01.005

48. Schneider J.J., Unholzer A., Schaller M., Schafer-Korting M., Korting H.C. Human defensins. J. Mol. Med. (Berl.) 2005; 83 (8): 587-595. doi: 10.1007/s00109-005-0657-1

49. Schutyser E., Richmond A., van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J. Leukoc. Biol. 2005; 78 (1): 14-26. doi: 10.1189/jlb.1204712

50. Sorensen GL1, Husby S., Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology. 2007; 212 (4-5): 381-416. doi: 10.1016/j.imbio.2007.01.003

51. Steppan C.M., Brown E.J., Wright C.M., Bhat S., Banerjee R.R., Dai C.Y., Enders G.H., Sil-berg D.G., Wen X., Wu G.D., Lazar M.A. A family of tissue-specific resistin-like molecules. Proc. Natl. Acad. Sci. USA. 2001; 98 (2): 502-506. doi: 10.1073/pnas.98.2.502

52. Van Vyve T., Chanez P., Bernard A., Bous-quet J., Godard P., Lauwerijs R., Sibille Y. Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects. J. Allergy Clin. Immunol. 1995; 95 (1, Pt. 1): 60-68. doi: S0091674995000121

53. Wert S.E., Yoshida M., LeVine A.M., Ikega-mi M., Jones T., Ross G.F., Fisher J.H., Korfhagen T.R., Whitsett J.A. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc. Natl. Acad. Sci. USA. 2000; 97 (11): 5972-5977. doi: 10.1073/pnas.100448997.

54. Wirestam L., Enocsson H., Skogh T., Elor-anta M.L., Ronnblom L., Sjowall C., Wettero J. Interferon-alpha coincides with suppressed levels of pen-traxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro. Clin. Exp. Immunol. 2017; 189 (1): 83-91. doi: 10.1111/cei.12957

55. Yoshie O., Imai T., Nomiyama H. Chemokines in immunity. Adv. Immunol. 2001; 78: 57-110.